{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:09:01Z","timestamp":1791828541473,"version":"4.3.4"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04341-5","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T06:20:25Z","timestamp":1753251625000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-550X","authenticated-orcid":false,"given":"Paola","family":"Loli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"4341_CR1","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0140-6736(22)01330-7","volume":"401","author":"MK Auer","year":"2023","unstructured":"M.K. Auer, A. Nordenstr\u00f6m, S. Lajic, N. Reisch, Congenital adrenal hyperplasia. Lancet 401, 227\u2013244 (2023). https:\/\/doi.org\/10.1016\/S0140-6736(22)01330-7.","journal-title":"Lancet"},{"key":"4341_CR2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1542\/pir.2022-005617","volume":"45","author":"NR Fraga","year":"2024","unstructured":"N.R. Fraga, N. Minaeian, M.S. Kim, Congenital adrenal hyperplasia. Pediatr. Rev. 45, 74\u201384 (2024). https:\/\/doi.org\/10.1542\/pir.2022-005617.","journal-title":"Pediatr. Rev."},{"key":"4341_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJM198507253130404","volume":"313","author":"F Kuttenn","year":"1985","unstructured":"F. Kuttenn, P. Couillin, F. Girard et al., Late-onset adrenal hyperplasia in hirsutism. N. Engl. J. Med. 313, 224\u2013231 (1985). https:\/\/doi.org\/10.1056\/NEJM198507253130404.","journal-title":"N. Engl. J. Med."},{"key":"4341_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ecl.2020.10.008","volume":"50","author":"S Jha","year":"2021","unstructured":"S. Jha, A.F. Turcu, Nonclassic congenital adrenal hyperplasia. Endocrinol. Metab. Clin. North. Am. 50, 151\u2013165 (2021). https:\/\/doi.org\/10.1016\/j.ecl.2020.10.008.","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"4341_CR5","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1210\/jc.2018-01865","volume":"103","author":"PW Speiser","year":"2018","unstructured":"P.W. Speiser, W. Arlt, R.J. Auchus et al., Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 4043\u20134088 (2018). https:\/\/doi.org\/10.1210\/jc.2018-01865.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1515\/jpem-2018-0398","volume":"32","author":"PS Castro","year":"2019","unstructured":"P.S. Castro, T.O. Rassi, R.F. Araujo et al., High frequency of non-classical congenital adrenal hyperplasia form among children with persistently elevated levels of 17-hydroxyprogesterone after newborn screening. J. Pediatr. Endocrinol. Metab. 32, 499\u2013504 (2019). https:\/\/doi.org\/10.1515\/jpem-2018-0398.","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"4341_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4274\/jcrpe.3378","volume":"9","author":"S Kurto\u011flu","year":"2017","unstructured":"S. Kurto\u011flu, N. Hatipo\u011flu, Non-classical congenital adrenal hyperplasia in childhood. J. Clin. Res. Pediatr. Endocrinol. 9, 1\u20137 (2017). https:\/\/doi.org\/10.4274\/jcrpe.3378.","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"4341_CR8","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/humupd\/dmx014","volume":"23","author":"E Carmina","year":"2017","unstructured":"E. Carmina, D. Dewailly, H.F. Escobar-Morreale et al., Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum. Reprod. Update 23, 580\u2013599 (2017). https:\/\/doi.org\/10.1093\/humupd\/dmx014.","journal-title":"Hum. Reprod. Update"},{"key":"4341_CR9","first-page":"650","volume":"37","author":"PW Speiser","year":"1985","unstructured":"P.W. Speiser, B. Dupont, P. Rubinstein et al., High frequency of nonclassical steroid 21-hydroxylase deficiency. Am. J. Hum. Genet. 37, 650\u2013667 (1985).","journal-title":"Am. J. Hum. Genet."},{"key":"4341_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1210\/jcem-69-4-709","volume":"69","author":"A Morris","year":"1989","unstructured":"A. Morris, E. Reiter, M. Geffner et al., Absence of nonclassical congenital adrenal hyperplasia in patients with precocious adrenarche. J. Clin. Endocrinol. Metab. 69, 709\u2013715 (1989). https:\/\/doi.org\/10.1210\/jcem-69-4-709.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/ijns9030050","volume":"9","author":"B McCann-Crosby","year":"2023","unstructured":"B. McCann-Crosby, M.C. Liang, M.E. Geffner et al., Differences in hyperandrogenism related to early detection of non-classical congenital adrenal hyperplasia on second newborn screen. Int. J. Neonatal Screen. 9, 50 (2023). https:\/\/doi.org\/10.3390\/ijns9030050.","journal-title":"Int. J. Neonatal Screen."},{"key":"4341_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12020-015-0656-0","volume":"50","author":"H Falhammar","year":"2015","unstructured":"H. Falhammar, A. Nordenstr\u00f6m, Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine 50, 32\u201350 (2015). https:\/\/doi.org\/10.1007\/s12020-015-0656-0.","journal-title":"Endocrine"},{"key":"4341_CR13","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"R. Azziz, L.A. Sanchez, E.S. Knochenhauer et al., Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89, 453\u2013462 (2004). https:\/\/doi.org\/10.1210\/jc.2003-031122.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR14","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"R. Azziz, E. Carmina, D. Dewailly et al., The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456\u2013488 (2009). https:\/\/doi.org\/10.1016\/j.fertnstert.2008.06.035.","journal-title":"Fertil. Steril."},{"key":"4341_CR15","first-page":"311","volume":"25","author":"C Mor\u00e1n","year":"1994","unstructured":"C. Mor\u00e1n, M.C. Tapia, E. Hern\u00e1ndez et al., Etiological review of hirsutism in 250 patients. Arch. Med. Res. 25, 311\u2013314 (1994).","journal-title":"Arch. Med. Res."},{"key":"4341_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/humupd\/dmr042","volume":"18","author":"HF Escobar-Morreale","year":"2012","unstructured":"H.F. Escobar-Morreale, E. Carmina, D. Dewailly et al., Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen excess and polycystic ovary syndrome society. Hum. Reprod. Update 18, 146\u2013170 (2012). https:\/\/doi.org\/10.1093\/humupd\/dmr042.","journal-title":"Hum. Reprod. Update"},{"key":"4341_CR17","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1365-2362.1992.tb01425.x","volume":"22","author":"M Arnaout","year":"1992","unstructured":"M. Arnaout, Late-onset congenital adrenal hyperplasia in women with hirsutism. Eur. J. Clin. Invest. 22, 651\u2013658 (1992). https:\/\/doi.org\/10.1111\/j.1365-2362.1992.tb01425.x.","journal-title":"Eur. J. Clin. Invest."},{"key":"4341_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.12816\/0002624","volume":"62","author":"RS Zreik","year":"2014","unstructured":"R.S. Zreik, M.P. Nasrallah, The prevalence of endocrinopathies among lebanese women presenting with hirsutism to an endocrine clinic. Leban. Med. J. 62, 27\u201332 (2014). https:\/\/doi.org\/10.12816\/0002624.","journal-title":"Leban. Med. J."},{"key":"4341_CR19","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1067\/mob.2000.108020","volume":"183","author":"C Moran","year":"2000","unstructured":"C. Moran, R. Azziz, E. Carmina et al., 21-Hydroxylase\u2013deficient nonclassic adrenal hyperplasia is a progressive disorder: a multicenter study. Am. J. Obstet. Gynecol. 183, 1468\u20131474 (2000). https:\/\/doi.org\/10.1067\/mob.2000.108020.","journal-title":"Am. J. Obstet. Gynecol."},{"key":"4341_CR20","doi-asserted-by":"publisher","first-page":"947762","DOI":"10.3389\/fendo.2022.947762","volume":"13","author":"W Lu","year":"2022","unstructured":"W. Lu, T. Zhang, L. Zhang et al., Clinical characteristics of a male child with non-classic lipoid congenital adrenal hyperplasia and literature review. Front. Endocrinol. 13, 947762 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.947762.","journal-title":"Front. Endocrinol."},{"key":"4341_CR21","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00431-007-0625-6","volume":"167","author":"M Wasniewska","year":"2008","unstructured":"M. Wasniewska, G. Raiola, M.C. Galati et al., Non-classical 21-hydroxylase deficiency in boys with prepubertal or pubertal gynecomastia. Eur. J. Pediatr. 167, 1083\u20131084 (2008). https:\/\/doi.org\/10.1007\/s00431-007-0625-6.","journal-title":"Eur. J. Pediatr."},{"key":"4341_CR22","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.fertnstert.2008.12.037","volume":"93","author":"H Pinkas","year":"2010","unstructured":"H. Pinkas, S. Fuchs, Y. Klipper-Aurbach et al., Non-classical 21-hydroxylase deficiency: prevalence in males with unexplained abnormal sperm analysis. Fertil. Steril. 93, 1887\u20131891 (2010). https:\/\/doi.org\/10.1016\/j.fertnstert.2008.12.037.","journal-title":"Fertil. Steril."},{"key":"4341_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1210\/jcem-48-2-356","volume":"48","author":"MI New","year":"1979","unstructured":"M.I. New, F. Lorenzen, S. Pang et al., \u201cAcquired\u201d adrenal hyperplasia with 21-hydroxylase deficiency is not the same genetic disorder as congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 48, 356\u2013359 (1979). https:\/\/doi.org\/10.1210\/jcem-48-2-356.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR24","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/S0140-6736(05)66736-0","volume":"365","author":"DP Merke","year":"2005","unstructured":"D.P. Merke, S.R. Bornstein, Congenital adrenal hyperplasia. Lancet 365, 2125\u20132136 (2005). https:\/\/doi.org\/10.1016\/S0140-6736(05)66736-0.","journal-title":"Lancet"},{"key":"4341_CR25","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1210\/jc.2008-1582","volume":"94","author":"M Bidet","year":"2009","unstructured":"M. Bidet, C. Bellann\u00e9-Chantelot, M.-B. Galand-Portier et al., Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J. Clin. Endocrinol. Metab. 94, 1570\u20131578 (2009). https:\/\/doi.org\/10.1210\/jc.2008-1582.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR26","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cen.12543","volume":"82","author":"S Livadas","year":"2015","unstructured":"S. Livadas, M. Dracopoulou, A. Dastamani et al., The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin. Endocrinol. 82, 543\u2013549 (2015). https:\/\/doi.org\/10.1111\/cen.12543.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR27","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1073\/pnas.1300057110","volume":"110","author":"MI New","year":"2013","unstructured":"M.I. New, M. Abraham, B. Gonzalez et al., Genotype\u2013phenotype correlation in 1507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc. Natl Acad. Sci. 110, 2611\u20132616 (2013). https:\/\/doi.org\/10.1073\/pnas.1300057110.","journal-title":"Proc. Natl Acad. Sci."},{"key":"4341_CR28","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00404-023-06946-5","volume":"308","author":"E Liu","year":"2023","unstructured":"E. Liu, H. Luo, K. Zhou, Y. Zhang, Clinical analysis of 78 patients with nonclassical 21-hydroxylase deficiency. Arch. Gynecol. Obstet. 308, 871\u2013882 (2023). https:\/\/doi.org\/10.1007\/s00404-023-06946-5.","journal-title":"Arch. Gynecol. Obstet."},{"key":"4341_CR29","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1046\/j.1365-2265.2000.00995.x","volume":"52","author":"TA Bachega","year":"2000","unstructured":"T.A. Bachega, A.E. Billerbeck, J.A. Marcondes et al., Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 52, 601\u2013607 (2000). https:\/\/doi.org\/10.1046\/j.1365-2265.2000.00995.x.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000337217","volume":"77","author":"KJ Pijnenburg-Kleizen","year":"2012","unstructured":"K.J. Pijnenburg-Kleizen, G.F. Borm, B.J. Otten et al., Absence of clinically relevant growth acceleration in untreated children with non-classical congenital adrenal hyperplasia. Horm. Res. Paediatr. 77, 164\u2013169 (2012). https:\/\/doi.org\/10.1159\/000337217.","journal-title":"Horm. Res. Paediatr."},{"key":"4341_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/apa.12147","volume":"102","author":"O Eyal","year":"2013","unstructured":"O. Eyal, Y. Tenenbaum-Rakover, S. Shalitin et al., Adult height of subjects with nonclassical 21-hydroxylase deficiency. Acta Paediatr. 102, 419\u2013423 (2013). https:\/\/doi.org\/10.1111\/apa.12147.","journal-title":"Acta Paediatr."},{"key":"4341_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1515\/JPEM.2007.20.8.883","volume":"20","author":"S Nimkarn","year":"2007","unstructured":"S. Nimkarn, M.I. New, K. Lin-Su, Growth and pubertal characteristics in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Pediatr. Endocrinol. Metab. 20, 883\u2013891 (2007). https:\/\/doi.org\/10.1515\/JPEM.2007.20.8.883.","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"4341_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.steroids.2013.04.010","volume":"78","author":"SF Witchel","year":"2013","unstructured":"S.F. Witchel, Non-classic congenital adrenal hyperplasia. Steroids 78, 747\u2013750 (2013). https:\/\/doi.org\/10.1016\/j.steroids.2013.04.010.","journal-title":"Steroids"},{"key":"4341_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-2265.1995.tb02034.x","volume":"43","author":"DJ Hoimes-Walker","year":"1995","unstructured":"D.J. Hoimes-Walker, G.S. Conway, J.W. Honour et al., Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 43, 291\u2013296 (1995). https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02034.x.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/cen.14842","volume":"98","author":"C Carri\u00e8re","year":"2023","unstructured":"C. Carri\u00e8re, L.S. Nguyen, C. Courtillot et al., Fertility and pregnancy outcomes in women with nonclassic 21-hydroxylase deficiency. Clin. Endocrinol. 98, 315\u2013322 (2023). https:\/\/doi.org\/10.1111\/cen.14842.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0015-0282(16)54592-0","volume":"56","author":"JH Levin","year":"1991","unstructured":"J.H. Levin, E. Carmina, R.A. Lobo, Is the inappropriate gonadotropin secretion of patients with polycystic ovary syndrome similar to that of patients with adult-onset congenital adrenal hyperplasia?. Fertil. Steril. 56, 635\u2013640 (1991). https:\/\/doi.org\/10.1016\/S0015-0282(16)54592-0.","journal-title":"Fertil. Steril."},{"key":"4341_CR37","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.fertnstert.2013.11.002","volume":"101","author":"DE Reichman","year":"2014","unstructured":"D.E. Reichman, P.C. White, M.I. New, Z. Rosenwaks, Fertility in patients with congenital adrenal hyperplasia. Fertil. Steril. 101, 301\u2013309 (2014). https:\/\/doi.org\/10.1016\/j.fertnstert.2013.11.002.","journal-title":"Fertil. Steril."},{"key":"4341_CR38","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0015-0282(98)00007-7","volume":"69","author":"MA Okon","year":"1998","unstructured":"M.A. Okon, S.M. Laird, E.M. Tuckerman, T.-C. Li, Serum androgen levels in women who have recurrent miscarriages and their correlation with markers of endometrial function. Fertil. Steril. 69, 682\u2013690 (1998). https:\/\/doi.org\/10.1016\/S0015-0282(98)00007-7.","journal-title":"Fertil. Steril."},{"key":"4341_CR39","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1210\/jc.2006-0062","volume":"91","author":"C Moran","year":"2006","unstructured":"C. Moran, R. Azziz, N. Weintrob et al., Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J. Clin. Endocrinol. Metab. 91, 3451\u20133456 (2006). https:\/\/doi.org\/10.1210\/jc.2006-0062.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR40","doi-asserted-by":"publisher","unstructured":"Bidet M., Bellanne\u0301-Chantelot C., Galand-Portier M.-B., et al (2010) Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 95:1182\u20131190. https:\/\/doi.org\/10.1210\/jc.2009-1383","DOI":"10.1210\/jc.2009-1383"},{"key":"4341_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ando.2022.04.007","volume":"83","author":"C Carri\u00e8re","year":"2022","unstructured":"C. Carri\u00e8re, C. Sarfati, I. T\u00e9j\u00e9dor et al., Classical and non-classical congenital adrenal hyperplasia: what is the difference in subsequent fertility?. Ann. Endocrinol. 83, 181\u2013185 (2022). https:\/\/doi.org\/10.1016\/j.ando.2022.04.007.","journal-title":"Ann. Endocrinol."},{"key":"4341_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12978-024-01874-2","volume":"21","author":"X Cui","year":"2024","unstructured":"X. Cui, P. Li, Clinical characteristics and treatment during preconception and perinatal period of infertile women with non-classical 21-hydroxylase deficiency. Reprod. Health 21, 139 (2024). https:\/\/doi.org\/10.1186\/s12978-024-01874-2.","journal-title":"Reprod. Health"},{"key":"4341_CR43","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1210\/jcem.86.7.7668","volume":"86","author":"MS Cabrera","year":"2001","unstructured":"M.S. Cabrera, M.G. Vogiatzi, M.I. New, Long term outcome in adult males with classic congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 86, 3070\u20133078 (2001). https:\/\/doi.org\/10.1210\/jcem.86.7.7668.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1530\/EJE-11-0828","volume":"166","author":"H Falhammar","year":"2012","unstructured":"H. Falhammar, H.F. Nystr\u00f6m, U. Ekstr\u00f6m et al., Fertility, sexuality and testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia. Eur. J. Endocrinol. 166, 441\u2013449 (2012). https:\/\/doi.org\/10.1530\/EJE-11-0828.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR45","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/clinem\/dgad546","volume":"109","author":"I Koren","year":"2024","unstructured":"I. Koren, N. Weintrob, R. Kebesch et al., Genotype-specific cortisol reserve in a cohort of subjects with nonclassic congenital adrenal hyperplasia (NCCAH). J. Clin. Endocrinol. Metab. 109, 852\u2013857 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgad546.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR46","doi-asserted-by":"publisher","first-page":"E346","DOI":"10.1210\/jc.2012-3343","volume":"98","author":"N Krone","year":"2013","unstructured":"N. Krone, I.T. Rose, D.S. Willis et al., Genotype-phenotype correlation in 153 adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: analysis of the United Kingdom Congenital Adrenal Hyperplasia Adult Study Executive (CaHASE) Cohort. J. Clin. Endocrinol. Metab. 98, E346\u2013E354 (2013). https:\/\/doi.org\/10.1210\/jc.2012-3343.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR47","doi-asserted-by":"publisher","unstructured":"H. Falhammar, Non-functioning adrenal incidentalomas caused by 21-hydroxylase deficiency or carrier status?. Endocrine 47, 308\u2013314 (2014). https:\/\/doi.org\/10.1007\/s12020-013-0162-1.","DOI":"10.1007\/s12020-013-0162-1"},{"key":"4341_CR48","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1210\/jc.2018-00208","volume":"103","author":"D El-Maouche","year":"2018","unstructured":"D. El-Maouche, C.J. Hargreaves, N. Sinaii et al., Longitudinal assessment of illnesses, stress dosing, and illness sequelae in patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 103, 2336\u20132345 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00208.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1210\/jcem.74.3.1311000","volume":"74","author":"S Jaresch","year":"1992","unstructured":"S. Jaresch, E. Kornely, H.K. Kley, R. Schlaghecke, Adrenal incidentaloma and patients with homozygous or heterozygous congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 74, 685\u2013689 (1992). https:\/\/doi.org\/10.1210\/jcem.74.3.1311000.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR50","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/j.1365-2265.2011.04151.x","volume":"75","author":"I Nermoen","year":"2011","unstructured":"I. Nermoen, J. R\u00f8rvik, S.H. Holmedal et al., High frequency of adrenal myelolipomas and testicular adrenal rest tumours in adult Norwegian patients with classical congenital adrenal hyperplasia because of 21-hydroxylase deficiency. Clin. Endocrinol. 75, 753\u2013759 (2011). https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04151.x.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR51","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1210\/jc.2009-1929","volume":"95","author":"N Reisch","year":"2010","unstructured":"N. Reisch, M. Scherr, L. Flade et al., Total adrenal volume but not testicular adrenal rest tumor volume is associated with hormonal control in patients with 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 95, 2065\u20132072 (2010). https:\/\/doi.org\/10.1210\/jc.2009-1929.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40618-022-01933-0","volume":"46","author":"F Sahlander","year":"2022","unstructured":"F. Sahlander, J. Patrova, B. Mannheimer et al., Congenital adrenal hyperplasia in patients with adrenal tumors: a population-based case\u2013control study. J. Endocrinol. Invest. 46, 559\u2013565 (2022). https:\/\/doi.org\/10.1007\/s40618-022-01933-0.","journal-title":"J. Endocrinol. Invest."},{"key":"4341_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0015-0282(16)54434-3","volume":"56","author":"R Azziz","year":"1991","unstructured":"R. Azziz, P.J. Kenney, Magnetic resonance imaging of the adrenal gland in women with late-onset adrenal hyperplasia. Fertil. Steril. 56, 142\u2013144 (1991). https:\/\/doi.org\/10.1016\/S0015-0282(16)54434-3.","journal-title":"Fertil. Steril."},{"key":"4341_CR54","doi-asserted-by":"publisher","first-page":"736","DOI":"10.4158\/EP151085.RA","volume":"22","author":"H Falhammar","year":"2016","unstructured":"H. Falhammar, D.J. Torpy, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency presenting as adrenal incidentaloma: a systematic review and meta-analysis. Endocr. Pract. 22, 736\u2013752 (2016). https:\/\/doi.org\/10.4158\/EP151085.RA.","journal-title":"Endocr. Pract."},{"key":"4341_CR55","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3390\/biomedicines11113081","volume":"11","author":"M Carsote","year":"2023","unstructured":"M. Carsote, A.-M. Gheorghe, C. Nistor et al., Landscape of adrenal tumours in patients with congenital adrenal hyperplasia. Biomedicines 11, 3081 (2023). https:\/\/doi.org\/10.3390\/biomedicines11113081.","journal-title":"Biomedicines"},{"key":"4341_CR56","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4158\/EP-2020-0058","volume":"26","author":"I Nermoen","year":"2020","unstructured":"I. Nermoen, H. Falhammar, Prevalence and characteristics of adrenal tumors and myelolipomas in congenital adrenal hyperplasia: a systematic review and meta-analysis. Endocr. Pract. 26, 1351\u20131365 (2020). https:\/\/doi.org\/10.4158\/EP-2020-0058.","journal-title":"Endocr. Pract."},{"key":"4341_CR57","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/2230-8210.119585","volume":"17","author":"T Varma","year":"2013","unstructured":"T. Varma, R. Panchani, A. Goyal, R. Maskey, A case of androgen-secreting adrenal carcinoma with non-classical congenital adrenal hyperplasia. Indian. J. Endocrinol. Metab. 17, 243 (2013). https:\/\/doi.org\/10.4103\/2230-8210.119585.","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"4341_CR58","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1365-2605.2009.00967.x","volume":"33","author":"A Mouritsen","year":"2010","unstructured":"A. Mouritsen, N. J\u00f8rgensen, K.M. Main et al., Testicular adrenal rest tumours in boys, adolescents and adult men with congenital adrenal hyperplasia may be associated with the CYP21A2 mutation. Int. J. Androl. 33, 521\u2013527 (2010). https:\/\/doi.org\/10.1111\/j.1365-2605.2009.00967.x.","journal-title":"Int. J. Androl."},{"key":"4341_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jpurol.2023.10.005","volume":"20","author":"L Eyer de Jesus","year":"2024","unstructured":"L. Eyer de Jesus, A.P. Paz de Oliveira, L.C. Porto, S. Dekermacher, Testicular adrenal rest tumors \u2013 Epidemiology, diagnosis and treatment. J. Pediatr. Urol. 20, 77\u201387 (2024). https:\/\/doi.org\/10.1016\/j.jpurol.2023.10.005.","journal-title":"J. Pediatr. Urol."},{"key":"4341_CR60","doi-asserted-by":"publisher","first-page":"562","DOI":"10.21037\/tau-20-998","volume":"10","author":"B Corcioni","year":"2021","unstructured":"B. Corcioni, M. Renzulli, G. Marasco et al., Prevalence and ultrasound patterns of testicular adrenal rest tumors in adults with congenital adrenal hyperplasia. Transl. Androl. Urol. 10, 562\u2013573 (2021). https:\/\/doi.org\/10.21037\/tau-20-998.","journal-title":"Transl. Androl. Urol."},{"key":"4341_CR61","doi-asserted-by":"publisher","unstructured":"Claahsen-van der Grinten H.L., Otten B.J., Sweep FCGJ, et al. (2007) Testicular tumors in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency show functional features of adrenocortical tissue. J Clin Endocrinol Metab 92:3674\u20133680. https:\/\/doi.org\/10.1210\/jc.2007-0337","DOI":"10.1210\/jc.2007-0337"},{"key":"4341_CR62","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1210\/jc.2010-0917","volume":"95","author":"W Arlt","year":"2010","unstructured":"W. Arlt, D.S. Willis, S.H. Wild et al., Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J. Clin. Endocrinol. Metab. 95, 5110\u20135121 (2010). https:\/\/doi.org\/10.1210\/jc.2010-0917.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR63","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1507\/endocrj.51.601","volume":"51","author":"F Bayraktar","year":"2004","unstructured":"F. Bayraktar, D. Dereli, A.G. Ozgen, C. Yilmaz, Plasma homocysteine levels in polycystic ovary syndrome and congenital adrenal hyperplasia. Endocr. J. 51, 601\u2013608 (2004). https:\/\/doi.org\/10.1507\/endocrj.51.601.","journal-title":"Endocr. J."},{"key":"4341_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/cen.14988","volume":"100","author":"M Pir\u00f3g","year":"2024","unstructured":"M. Pir\u00f3g, A. Pulka, E. Zabieg\u0142o, R. Jach, Nonclassical congenital adrenal hyperplasia: Metabolic and hormonal profile. Clin. Endocrinol. 100, 109\u2013115 (2024). https:\/\/doi.org\/10.1111\/cen.14988.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2265.2009.03587.x","volume":"72","author":"RM Williams","year":"2010","unstructured":"R.M. Williams, A. Deeb, K.K. Ong et al., Insulin sensitivity and body composition in children with classical and nonclassical congenital adrenal hyperplasia. Clin. Endocrinol. 72, 155\u2013160 (2010). https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03587.x.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR66","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12020-010-9382-9","volume":"38","author":"H-J Zhang","year":"2010","unstructured":"H.-J. Zhang, J. Yang, M.-N. Zhang et al., Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency. Endocrine 38, 260\u2013265 (2010). https:\/\/doi.org\/10.1007\/s12020-010-9382-9.","journal-title":"Endocrine"},{"key":"4341_CR67","doi-asserted-by":"publisher","first-page":"E2715","DOI":"10.1210\/jc.2014-2957","volume":"99","author":"H Falhammar","year":"2014","unstructured":"H. Falhammar, L. Fris\u00e9n, C. Norrby et al., Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 99, E2715\u2013E2721 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2957.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR68","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3389\/fendo.2019.00698","volume":"10","author":"L de Vries","year":"2019","unstructured":"L. de Vries, Y. Lebenthal, M. Phillip et al., Obesity and cardiometabolic risk factors in children and young adults with non-classical 21-hydroxylase deficiency. Front. Endocrinol. 10, 698 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00698.","journal-title":"Front. Endocrinol."},{"key":"4341_CR69","doi-asserted-by":"publisher","unstructured":"R. Krysiak, H.L. Claahsen-van der Grinten, N. Reisch, et al. Cardiometabolic aspects of congenital adrenal hyperplasia. Endocr. Rev. (2024). https:\/\/doi.org\/10.1210\/endrev\/bnae026","DOI":"10.1210\/endrev\/bnae026"},{"key":"4341_CR70","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3389\/fendo.2019.00681","volume":"10","author":"D Macut","year":"2019","unstructured":"D. Macut, V. Zdravkovi\u0107, J. Bjeki\u0107-Macut et al., Metabolic perspectives for non-classical congenital adrenal hyperplasia with relation to the classical form of the disease. Front. Endocrinol. 10, 681 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00681.","journal-title":"Front. Endocrinol."},{"key":"4341_CR71","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1210\/clinem\/dgae155","volume":"110","author":"FC Costa","year":"2024","unstructured":"F.C. Costa, L.G. Gomes, T.M. de Lima et al., Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 110, e72\u2013e79 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgae155.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR72","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1055\/s-0034-1382048","volume":"122","author":"R Krysiak","year":"2014","unstructured":"R. Krysiak, B. Okopien, The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. Exp. Clin. Endocrinol. Diabetes 122, 568\u2013571 (2014). https:\/\/doi.org\/10.1055\/s-0034-1382048.","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"4341_CR73","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1210\/jc.2007-0744","volume":"92","author":"H Falhammar","year":"2007","unstructured":"H. Falhammar, H. Filipsson, G. Holmdahl et al., Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92, 4643\u20134649 (2007). https:\/\/doi.org\/10.1210\/jc.2007-0744.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR74","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cen.12507","volume":"82","author":"D El-Maouche","year":"2015","unstructured":"D. El-Maouche, S. Collier, M. Prasad et al., Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin. Endocrinol. 82, 330\u2013337 (2015). https:\/\/doi.org\/10.1111\/cen.12507.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR75","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1530\/EJE-07-0887","volume":"158","author":"Z Chakhtoura","year":"2008","unstructured":"Z. Chakhtoura, A. Bachelot, D. Samara-Boustani et al., Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol. 158, 879\u2013887 (2008). https:\/\/doi.org\/10.1530\/EJE-07-0887.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR76","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3389\/fendo.2020.00493","volume":"11","author":"S Rangaswamaiah","year":"2020","unstructured":"S. Rangaswamaiah, V. Gangathimmaiah, A. Nordenstrom, H. Falhammar, Bone mineral density in adults with congenital adrenal hyperplasia: a systematic review and meta-analysis. Front. Endocrinol. 11, 493 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00493.","journal-title":"Front. Endocrinol."},{"key":"4341_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-022-01090-0","volume":"17","author":"DH Lee","year":"2022","unstructured":"D.H. Lee, S.H. Kong, H.N. Jang et al., Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency. Arch. Osteoporos. 17, 45 (2022). https:\/\/doi.org\/10.1007\/s11657-022-01090-0.","journal-title":"Arch. Osteoporos."},{"key":"4341_CR78","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1210\/jc.2012-2102","volume":"97","author":"GP Finkielstain","year":"2012","unstructured":"G.P. Finkielstain, M.S. Kim, N. Sinaii et al., Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 97, 4429\u20134438 (2012). https:\/\/doi.org\/10.1210\/jc.2012-2102.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR79","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/MAJ.0b013e31824369e4","volume":"344","author":"MF Mnif","year":"2012","unstructured":"M.F. Mnif, M. Kamoun, F. Mnif et al., Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Am. J. Med. Sci. 344, 363\u2013373 (2012). https:\/\/doi.org\/10.1097\/MAJ.0b013e31824369e4.","journal-title":"Am. J. Med. Sci."},{"key":"4341_CR80","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.jsbmb.2020.105734","volume":"204","author":"MK Auer","year":"2020","unstructured":"M.K. Auer, L. Paizoni, L.C. Hofbauer et al., Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol. 204, 105734 (2020). https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105734.","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"4341_CR81","doi-asserted-by":"publisher","first-page":"1456679","DOI":"10.3389\/fped.2024.1456679","volume":"12","author":"R Navardauskaite","year":"2024","unstructured":"R. Navardauskaite, A. Vanckaviciene, R. Verkauskiene, Bone mineral density determinants in adolescents and young adults with congenital adrenal hyperplasia. Front. Pediatr. 12, 1456679 (2024). https:\/\/doi.org\/10.3389\/fped.2024.1456679.","journal-title":"Front. Pediatr."},{"key":"4341_CR82","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cen.14149","volume":"92","author":"G Riehl","year":"2020","unstructured":"G. Riehl, N. Reisch, R. Roehle et al., Bone mineral density and fractures in congenital adrenal hyperplasia: Findings from the dsd-LIFE study. Clin. Endocrinol. 92, 284\u2013294 (2020). https:\/\/doi.org\/10.1111\/cen.14149.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR83","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1046\/j.1365-2265.1996.00851.x","volume":"45","author":"C Guo","year":"1996","unstructured":"C. Guo, A.P. Weetman, R. Eastell, Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin. Endocrinol. 45, 535\u2013541 (1996). https:\/\/doi.org\/10.1046\/j.1365-2265.1996.00851.x.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR84","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/cen.14809","volume":"99","author":"P Wiromrat","year":"2023","unstructured":"P. Wiromrat, P. Namphaisan, N. Wongsurawat et al., Elevated bone turnover markers predict bone mineral density accrual in adolescents with 21-hydroxylase deficiency. Clin. Endocrinol. 99, 462\u2013469 (2023). https:\/\/doi.org\/10.1111\/cen.14809.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR85","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00223-023-01132-w","volume":"113","author":"X Sun","year":"2023","unstructured":"X. Sun, Y. Wu, L. Lu et al., Bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with 21- and 17\u03b1-hydroxylase deficiency. Calcif. Tissue Int. 113, 515\u2013525 (2023). https:\/\/doi.org\/10.1007\/s00223-023-01132-w.","journal-title":"Calcif. Tissue Int."},{"key":"4341_CR86","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-12-0865","volume":"168","author":"H Falhammar","year":"2013","unstructured":"H. Falhammar, H. Filipsson Nystr\u00f6m, A. Wedell et al., Bone mineral density, bone markers, and fractures in adult males with congenital adrenal hyperplasia. Eur. J. Endocrinol. 168, 331\u2013341 (2013). https:\/\/doi.org\/10.1530\/EJE-12-0865.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR87","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3803\/EnM.2021.1328","volume":"37","author":"JH Kim","year":"2022","unstructured":"J.H. Kim, S. Choi, Y.A. Lee et al., Epidemiology and long-term adverse outcomes in Korean patients with congenital adrenal hyperplasia: a nationwide study. Endocrinol. Metab. 37, 138\u2013147 (2022). https:\/\/doi.org\/10.3803\/EnM.2021.1328.","journal-title":"Endocrinol. Metab."},{"key":"4341_CR88","doi-asserted-by":"publisher","first-page":"e475","DOI":"10.1210\/clinem\/dgab712","volume":"107","author":"H Falhammar","year":"2022","unstructured":"H. Falhammar, L. Fris\u00e9n, A.L. Hirschberg et al., Increased prevalence of fractures in congenital adrenal hyperplasia: a swedish population-based national cohort study. J. Clin. Endocrinol. Metab. 107, e475\u2013e486 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgab712.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR89","doi-asserted-by":"publisher","unstructured":"M.E. Flokas, L. Yang, K.R. Middleton, et al, CAHQL: a patient-reported outcome instrument to assess health-related quality of life in congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2024). https:\/\/doi.org\/10.1210\/clinem\/dgae309","DOI":"10.1210\/clinem\/dgae309"},{"key":"4341_CR90","doi-asserted-by":"publisher","unstructured":"M.J. Ferreira, R. Moita, M. Canha, et al. Quality of life in children diagnosed with non-classic congenital adrenal hyperplasia. Cureus. (2021). https:\/\/doi.org\/10.7759\/cureus.18937","DOI":"10.7759\/cureus.18937"},{"key":"4341_CR91","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1210\/jc.2013-3326","volume":"99","author":"A Strandqvist","year":"2014","unstructured":"A. Strandqvist, H. Falhammar, P. Lichtenstein et al., Suboptimal psychosocial outcomes in patients with congenital adrenal hyperplasia: Epidemiological Studies in a Nonbiased National Cohort in Sweden. J. Clin. Endocrinol. Metab. 99, 1425\u20131432 (2014). https:\/\/doi.org\/10.1210\/jc.2013-3326.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4341_CR92","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"H.J. Teede, C.T. Tay, J.J.E. Laven et al., Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 108 (10), 2447\u20132469 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad463.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR93","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/EJE-18-0712","volume":"180","author":"A Nordenstr\u00f6m","year":"2019","unstructured":"A. Nordenstr\u00f6m, H. Falhammar, Management of endocrine disease: diagnosis and management of the patient with non-classic CAH due to 21-hydroxylase deficiency. Eur. J. Endocrinol. 180, R127\u2013R145 (2019). https:\/\/doi.org\/10.1530\/EJE-18-0712.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR94","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1210\/jc.2007-2053","volume":"93","author":"HF Escobar-Morreale","year":"2008","unstructured":"H.F. Escobar-Morreale, R. Sancho\u0301n, J.L. San Milla\u0301n, A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J. Clin. Endocrinol. Metab. 93, 527\u2013533 (2008). https:\/\/doi.org\/10.1210\/jc.2007-2053.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR95","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1001\/jamapediatrics.2013.5321","volume":"168","author":"S Gidl\u00f6f","year":"2014","unstructured":"S. Gidl\u00f6f, A. Wedell, C. Guthenberg et al., Nationwide neonatal screening for congenital adrenal hyperplasia in Sweden. JAMA Pediatr. 168, 567 (2014). https:\/\/doi.org\/10.1001\/jamapediatrics.2013.5321.","journal-title":"JAMA Pediatr."},{"key":"4341_CR96","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jped.2018.06.003","volume":"95","author":"SF Witchel","year":"2019","unstructured":"S.F. Witchel, Newborn screening for congenital adrenal hyperplasia: beyond 17-hydroxyprogesterone concentrations. J. Pediatr. 95, 257\u2013259 (2019). https:\/\/doi.org\/10.1016\/j.jped.2018.06.003.","journal-title":"J. Pediatr."},{"key":"4341_CR97","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrendo.2009.148","volume":"5","author":"PC White","year":"2009","unstructured":"P.C. White, Neonatal screening for congenital adrenal hyperplasia. Nat. Rev. Endocrinol. 5, 490\u2013498 (2009). https:\/\/doi.org\/10.1038\/nrendo.2009.148.","journal-title":"Nat. Rev. Endocrinol."},{"key":"4341_CR98","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12020-015-0731-6","volume":"50","author":"H Falhammar","year":"2015","unstructured":"H. Falhammar, A. Wedell, A. Nordenstr\u00f6m, Biochemical and genetic diagnosis of 21-hydroxylase deficiency. Endocrine 50, 306\u2013314 (2015). https:\/\/doi.org\/10.1007\/s12020-015-0731-6.","journal-title":"Endocrine"},{"key":"4341_CR99","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1210\/edrv.21.3.0398","volume":"21","author":"PC White","year":"2000","unstructured":"P.C. White, P.W. Speiser, Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr. Rev. 21, 245\u2013291 (2000). https:\/\/doi.org\/10.1210\/edrv.21.3.0398.","journal-title":"Endocr. Rev."},{"key":"4341_CR100","doi-asserted-by":"publisher","first-page":"e1560","DOI":"10.1210\/clinem\/dgad377","volume":"108","author":"JL Ng","year":"2023","unstructured":"J.L. Ng, E.M. Lim, R. Zhang et al., Serum 21-deoxycortisol for diagnosis of nonclassic congenital adrenal hyperplasia in women with androgen excess. J. Clin. Endocrinol. Metab. 108, e1560\u2013e1570 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad377.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR101","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2009-2631","volume":"95","author":"PW Speiser","year":"2010","unstructured":"P.W. Speiser, R. Azziz, L.S. Baskin et al., Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133\u20134160 (2010). https:\/\/doi.org\/10.1210\/jc.2009-2631.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR102","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12020-011-9591-x","volume":"41","author":"H Falhammar","year":"2012","unstructured":"H. Falhammar, M. Thor\u00e9n, Clinical outcomes in the management of congenital adrenal hyperplasia. Endocrine 41, 355\u2013373 (2012). https:\/\/doi.org\/10.1007\/s12020-011-9591-x.","journal-title":"Endocrine"},{"key":"4341_CR103","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1530\/EJE-11-0019","volume":"164","author":"R Nandagopal","year":"2011","unstructured":"R. Nandagopal, N. Sinaii, N.A. Avila et al., Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families. Eur. J. Endocrinol. 164, 977\u2013984 (2011). https:\/\/doi.org\/10.1530\/EJE-11-0019.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR104","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1055\/s-2003-43307","volume":"21","author":"C Moran","year":"2003","unstructured":"C. Moran, R. Azziz, 21-hydroxylase-deficient nonclassic adrenal hyperplasia: the great pretender. Semin. Reprod. Med. 21, 295\u2013300 (2003). https:\/\/doi.org\/10.1055\/s-2003-43307.","journal-title":"Semin. Reprod. Med."},{"key":"4341_CR105","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1210\/jcem-63-2-418","volume":"63","author":"D Dewailly","year":"1986","unstructured":"D. Dewailly, M.C. Vantyghem-haudiquet, C. Sainsard et al., Clinical and biological phenotypes in late-onset 21 hydroxylase deficiency. J. Clin. Endocrinol. Metab. 63, 418\u2013423 (1986). https:\/\/doi.org\/10.1210\/jcem-63-2-418.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR106","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0015-0282(16)56998-2","volume":"62","author":"E Carmina","year":"1994","unstructured":"E. Carmina, R.A. Lobo, Ovarian suppression reduces clinical and endocrine expression of late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Fertil. Steril. 62, 738\u2013743 (1994). https:\/\/doi.org\/10.1016\/S0015-0282(16)56998-2.","journal-title":"Fertil. Steril."},{"key":"4341_CR107","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.fertnstert.2009.06.025","volume":"94","author":"M Pall","year":"2010","unstructured":"M. Pall, R. Azziz, J. Beires, D. Pignatelli, The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase\u2013deficient nonclassic adrenal hyperplasia. Fertil. Steril. 94, 684\u2013689 (2010). https:\/\/doi.org\/10.1016\/j.fertnstert.2009.06.025.","journal-title":"Fertil. Steril."},{"key":"4341_CR108","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fendo.2019.00388","volume":"10","author":"G Papadakis","year":"2019","unstructured":"G. Papadakis, E.A. Kandaraki, E. Tseniklidi et al., Polycystic ovary syndrome and NC-CAH: distinct characteristics and common findings. a systematic review. Front. Endocrinol. 10, 388 (2019). https:\/\/doi.org\/10.3389\/fendo.2019.00388.","journal-title":"Front. Endocrinol."},{"key":"4341_CR109","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.fertnstert.2022.05.012","volume":"118","author":"G\u00c5 Ueland","year":"2022","unstructured":"G.\u00c5 Ueland, S.R. Dahl, P. Methlie et al., Adrenal steroid profiling as a diagnostic tool to differentiate polycystic ovary syndrome from nonclassic congenital adrenal hyperplasia: pinpointing easy screening possibilities and normal cutoff levels using liquid chromatography tandem mass spectrometry. Fertil. Steril. 118, 384\u2013391 (2022). https:\/\/doi.org\/10.1016\/j.fertnstert.2022.05.012.","journal-title":"Fertil. Steril."},{"key":"4341_CR110","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1210\/jcem-68-3-542","volume":"68","author":"J Fiet","year":"1989","unstructured":"J. Fiet, B. Gueux, M.C. Rauxdemay et al., Increased plasma 21-deoxycorticosterone (21-DB) levels in late-onset adrenal 21-hydroxylase deficiency suggest a mild defect of the mineralocorticoid pathway. J. Clin. Endocrinol. Metab. 68, 542\u2013547 (1989). https:\/\/doi.org\/10.1210\/jcem-68-3-542.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR111","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/BF03345586","volume":"31","author":"H Falhammar","year":"2008","unstructured":"H. Falhammar, M. Thor\u00e9n, K. Hagenfeldt, A 31-year-old woman with infertility and polycystic ovaries diagnosed with non-classic congenital adrenal hyperplasia due to a novel CYP21 mutation. J. Endocrinol. Invest. 31, 176\u2013180 (2008). https:\/\/doi.org\/10.1007\/BF03345586.","journal-title":"J. Endocrinol. Invest."},{"key":"4341_CR112","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1210\/jcem.84.4.5584","volume":"84","author":"A Nordenstr\u00f6m","year":"1999","unstructured":"A. Nordenstr\u00f6m, C. Marcus, M. Axelson et al., Failure of cortisone acetate treatment in congenital adrenal hyperplasia because of defective 11\u03b2-hydroxysteroid dehydrogenase reductase activity. J. Clin. Endocrinol. Metab. 84, 1210\u20131213 (1999). https:\/\/doi.org\/10.1210\/jcem.84.4.5584.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR113","doi-asserted-by":"publisher","unstructured":"M. Auer, H. Nowotny, M. Quinkler, et al, Salivary steroid and 11-oxygenated androgen profiles in patients with congenital adrenal hyperplasia on various glucocorticoid replacement regimens. Endocr Abstr. (2021). https:\/\/doi.org\/10.1530\/endoabs.73.PEP1.1","DOI":"10.1530\/endoabs.73.PEP1.1"},{"key":"4341_CR114","doi-asserted-by":"publisher","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","volume":"106","author":"DP Merke","year":"2021","unstructured":"D.P. Merke, A. Mallappa, W. Arlt et al., Modified-release hydrocortisone in congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 106, e2063\u2013e2077 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgab051.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR115","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1210\/jc.2014-3809","volume":"100","author":"A Mallappa","year":"2015","unstructured":"A. Mallappa, N. Sinaii, P. Kumar et al., A phase 2 study of chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 100, 1137\u20131145 (2015). https:\/\/doi.org\/10.1210\/jc.2014-3809.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR116","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/cen.12316","volume":"80","author":"MJ Whitaker","year":"2014","unstructured":"M.J. Whitaker, M. Debono, H. Huatan et al., An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure. Clin. Endocrinol. 80, 554\u2013561 (2014). https:\/\/doi.org\/10.1111\/cen.12316.","journal-title":"Clin. Endocrinol."},{"key":"4341_CR117","doi-asserted-by":"publisher","first-page":"e240150","DOI":"10.1530\/EC-24-0150","volume":"13","author":"DA Rees","year":"2024","unstructured":"D.A. Rees, D.P. Merke, W. Arlt et al., Comparison of modified-release hydrocortisone capsules versus prednisolone in the treatment of congenital adrenal hyperplasia. Endocr. Connect. 13, e240150 (2024). https:\/\/doi.org\/10.1530\/EC-24-0150.","journal-title":"Endocr. Connect."},{"key":"4341_CR118","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s12020-021-02649-6","volume":"71","author":"H Nowotny","year":"2021","unstructured":"H. Nowotny, S.F. Ahmed, S. Bensing et al., Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis. Endocrine 71, 586\u2013594 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02649-6.","journal-title":"Endocrine"},{"key":"4341_CR119","doi-asserted-by":"publisher","first-page":"1101843","DOI":"10.3389\/fendo.2023.1101843","volume":"14","author":"SC Liu","year":"2023","unstructured":"S.C. Liu, M. Suresh, M. Jaber et al., Case report: anastrozole as a monotherapy for pre-pubertal children with non-classic congenital adrenal hyperplasia. Front. Endocrinol. 14, 1101843 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1101843.","journal-title":"Front. Endocrinol."},{"key":"4341_CR120","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.steroids.2011.12.009","volume":"77","author":"CM Trapp","year":"2012","unstructured":"C.M. Trapp, S.E. Oberfield, Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids 77, 342\u2013346 (2012). https:\/\/doi.org\/10.1016\/j.steroids.2011.12.009.","journal-title":"Steroids"},{"key":"4341_CR121","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1210\/jcem-70-3-642","volume":"70","author":"P Spritzer","year":"1990","unstructured":"P. Spritzer, L. Billaud, J.-C. Thalabard et al., Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 70, 642\u2013646 (1990). https:\/\/doi.org\/10.1210\/jcem-70-3-642.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR122","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1210\/jc.2018-00241","volume":"103","author":"KA Martin","year":"2018","unstructured":"K.A. Martin, R.R. Anderson, R.J. Chang et al., Evaluation and treatment of hirsutism in premenopausal women: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 103, 1233\u20131257 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00241.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR123","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jaad.2006.09.025","volume":"57","author":"I Hamzavi","year":"2007","unstructured":"I. Hamzavi, E. Tan, J. Shapiro, H. Lui, A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. J. Am. Acad. Dermatol. 57, 54\u201359 (2007). https:\/\/doi.org\/10.1016\/j.jaad.2006.09.025.","journal-title":"J. Am. Acad. Dermatol."},{"key":"4341_CR124","doi-asserted-by":"publisher","first-page":"CD010334","DOI":"10.1002\/14651858.CD010334.pub2","volume":"2015","author":"EJ van Zuuren","year":"2015","unstructured":"E.J. van Zuuren, Z. Fedorowicz, B. Carter, N. Pandis, Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst. Rev. 2015, CD010334 (2015). https:\/\/doi.org\/10.1002\/14651858.CD010334.pub2.","journal-title":"Cochrane Database Syst. Rev."},{"key":"4341_CR125","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-21-0794","volume":"186","author":"A Prete","year":"2022","unstructured":"A. Prete, R.J. Auchus, R.J. Ross, Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia. Eur. J. Endocrinol. 186, R1\u2013R14 (2022). https:\/\/doi.org\/10.1530\/EJE-21-0794.","journal-title":"Eur. J. Endocrinol."},{"key":"4341_CR126","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1210\/clinem\/dgab749","volume":"107","author":"RJ Auchus","year":"2022","unstructured":"R.J. Auchus, K. Sarafoglou, P.Y. Fechner et al., Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. 107, 801\u2013812 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgab749.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4341_CR127","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ando.2023.01.008","volume":"84","author":"B Dreves","year":"2023","unstructured":"B. Dreves, Y. Reznik, A. Tabarin, Congenital adrenal hyperplasia: new biomarkers and adult treatments. Ann. Endocrinol. 84, 472\u2013480 (2023). https:\/\/doi.org\/10.1016\/j.ando.2023.01.008.","journal-title":"Ann. Endocrinol."},{"key":"4341_CR128","doi-asserted-by":"publisher","unstructured":"K. Sarafoglou, M.S. Kim, M. Lodish, et al, Phase 3 trial of crinecerfont in pediatric congenital adrenal hyperplasia. N. Engl. J. Med. (2024). https:\/\/doi.org\/10.1056\/NEJMoa2404655","DOI":"10.1056\/NEJMoa2404655"},{"key":"4341_CR129","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1055\/s-0033-1355383","volume":"121","author":"R Krysiak","year":"2013","unstructured":"R. Krysiak, B. Okopien, The effect of simvastatin treatment on plasma steroid levels in females with non-classic congenital adrenal hyperplasia. Exp. Clin. Endocrinol. Diabetes 121, 643\u2013646 (2013). https:\/\/doi.org\/10.1055\/s-0033-1355383.","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"4341_CR130","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11154-022-09770-5","volume":"24","author":"JY Maher","year":"2023","unstructured":"J.Y. Maher, V. Gomez-Lobo, D.P. Merke, The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Rev. Endocr. Metab. Disord. 24, 71\u201383 (2023). https:\/\/doi.org\/10.1007\/s11154-022-09770-5.","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"4341_CR131","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.yhbeh.2010.06.007","volume":"59","author":"A Harris","year":"2011","unstructured":"A. Harris, J. Seckl, Glucocorticoids, prenatal stress and the programming of disease. Horm. Behav. 59, 279\u2013289 (2011). https:\/\/doi.org\/10.1016\/j.yhbeh.2010.06.007.","journal-title":"Horm. Behav."},{"key":"4341_CR132","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1210\/jc.2016-1543","volume":"101","author":"L Wallensteen","year":"2016","unstructured":"L. Wallensteen, M. Zimmermann, M. Thomsen Sandberg et al., Sex-dimorphic effects of prenatal treatment with dexamethasone. J. Clin. Endocrinol. Metab. 101, 3838\u20133846 (2016). https:\/\/doi.org\/10.1210\/jc.2016-1543.","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04341-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04341-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:27Z","timestamp":1758772827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04341-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4341"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04341-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}